期刊
CANCER CELL
卷 29, 期 1, 页码 32-48出版社
CELL PRESS
DOI: 10.1016/j.ccell.2015.12.007
关键词
-
资金
- Bloodwise
- Cancer Research UK (CRUK)
- Cancer Research UK [16753] Funding Source: researchfish
- Medical Research Council [MC_UP_1102/1, G0800892] Funding Source: researchfish
- MRC [MC_UP_1102/1, G0800892] Funding Source: UKRI
Transcriptional deregulation plays a major role in acute myeloid leukemia, and therefore identification of epigenetic modifying enzymes essential for the maintenance of oncogenic transcription programs holds the key to better understanding of the biology and designing effective therapeutic strategies for the disease. Here we provide experimental evidence for the functional involvement and therapeutic potential of targeting PRMT1, an H4R3 methyltransferase, in various MLL and non-MLL leukemias. PRMT1 is necessary but not sufficient for leukemic transformation, which requires co-recruitment of KDM4C, an H3K9 demethylase, by chimeric transcription factors to mediate epigenetic reprogramming. Pharmacological inhibition of KDM4C/PRMT1 suppresses transcription and transformation ability of MLL fusions and MOZ-TIF2, revealing a tractable aberrant epigenetic circuitry mediated by KDM4C and PRMT1 in acute leukemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据